CD274 and non-small cell lung carcinoma: If larger studies confirm this suggested trend towards better outcomes with immunotherapy in KRAS G12C, PD-L1 overexpressed (≥50%) NSCLC, it would be logical to explore the upfront use of sotorasib in PD-L1 low/negative, KRAS G12C NSCLC compared to the actual standard of chemo-immunotherapy [6,24]; while the PD-L1 high subgroup would continue to be treated with ICIs in the first-line, given the relatively high likelihood of a durable response.